FDAnews
www.fdanews.com/articles/132375-diabetes-cardiovascular-drug-developer-phasebio-adds-15-million

Diabetes, Cardiovascular Drug Developer PhaseBio Adds $15 Million

December 3, 2010
The Philadelphia-area biopharma company PhaseBio Pharmaceuticals has received the final $15 million of a $25 million investment to fund further testing of its lead drug, which focuses on hyperglycemia related to Type 2 diabetes.
MedCity News